Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Sarcomatoid Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Patients With Sarcomatoid Renal Cell Carcinoma – Re-Defining the First-Line of Treatment: A Meta-Analysis of Randomised Clinical Trials With Immune Checkpoint Inhibitors
Eur. J. Cancer 2020 Jul 23;136(xx)195-203, R Iacovelli, C Ciccarese, E Bria, S Bracarda, C Porta, G Procopio, G TortoraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.